# Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

> **NCT01516944** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hebei Medical University** · enrollment: 749 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
- **DRUG:** Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin
- **DRUG:** Oxaliplatin; Capecitabine

## Key facts

- **NCT ID:** NCT01516944
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2018-04
- **Final completion:** 2018-12
- **Target enrollment:** 749 (ACTUAL)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516944, "Perioperative Chemotherapy for Potentially Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01516944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*